ClinicalTrials.gg
CompletedNCT01684410Updated Feb 8, 2016Results posted

Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis

A Phase 2 interventional study of Alpha-1 HC 100 mg and Placebo in Cystic Fibrosis, sponsored by Grifols Therapeutics LLC. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-02-08.

Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 717 studies in Cystic Fibrosis with a site in United States — 86 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.

Enrollment
283rd of 517
30 · median 36
Started
2012
with 30 others
Phase 2
103 of 717
10 open now
Registered
248th of 717
by date

Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 283rd largest by enrollment of the 517 interventional ones that give a count, is one of 31 that started in 2012, is one of 103 in phase 2, and was the 248th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

86 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:

81 more — sign in →

All 86 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 717 studies in Cystic Fibrosis with a site in United States, or all of them as a file.
02

Study summary

This was a randomized, double-blind, placebo-controlled, dose escalation study to assess the safety and tolerability of 100 mg and 200 mg of inhaled Alpha-1 HC administered once a day for three weeks in subjects aged 18 years and older with cystic fibrosis (CF). The treatment duration in this study was intended to provide multi-dose safety information prior to proceeding to longer durations of exposure.

03

Conditions studied

  • Cystic Fibrosis

Keywords

  • Cystic Fibrosis
  • Alpha1-proteinase inhibitor
  • Alpha1-antitrypsin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Documentation of CF diagnosis.
  • Have a pre-bronchodilator ≥ 40% of predicted at Visit 1 and have a Visit 2 pre- product FEV1 that is ≥ 40% of predicted and within ± 15% of the Visit 1 result.
  • Deemed by the Investigator to be a suitable candidate for serial collection of expectorated sputum.

Exclusion criteria

Exclusion Criteria:

  • Had a pulmonary exacerbation during the 4 weeks before screening (Visit 1) which required the initiation of new antibiotic treatment
  • Have a pulmonary exacerbation during the screening period (between Visit 1 and Visit 2) which requires the initiation of new antibiotic treatment
  • \< 0.59 liters at the screening visit
  • Respiratory insufficiency with continuous supplemental oxygen therapy, or carbon dioxide retention
  • Elevated (AST) or alanine aminotransferase (ALT) that is ≥ 3 times the for age and gender
  • Smoking during the past 6 months
  • Lung surgery during the past 2 years
  • Positive culture for Burkholderia cepacia or mycobacterium during the past two years.
  • Active allergic bronchopulmonary aspergillosis
  • Pre-treatment sputum collection at Visit 1 or Visit 2 (Randomization) characterized by problems such as inadequate sputum volume or quality.
  • Known selective Immunoglobulin A (IgA) deficiency with known antibody against IgA (anti-IgA antibody).
  • History of anaphylaxis or severe systemic response to any plasma-derived alpha1-proteinase inhibitor preparation or other blood product(s), or to polysorbates.
  • Use of chronic oral during the study. Note: Inhaled corticosteroids that had been administered for at least 4 weeks prior to Visit 1 were permissible during the study.
  • Use of chronic, high dose ibuprofen therapy within 3 weeks of screening and at anytime during the study.
  • Chronic maintenance therapy with systemic antibiotics within 3 weeks of screening and through last dose of product.
  • Use of leukotriene synthesis inhibitor (zileuton) or leukotriene receptor antagonists (montelukast, zafirlukast) within 3 weeks of screening and at anytime during the study.
  • Use of roflumilast within 3 weeks of screening and at any time during the study.
  • Initiation of a new chronic medication or dosage change of a chronic medication for treatment of cystic fibrosis (example: Kalydeco™ [ivacaftor]) within 3 weeks of screening (Visit 1).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Alpha-1 HC 100 mg

    100 mg of aerosolized Alpha-1 HC inhaled daily via nebulizer for 3 weeks.

    Biological: Alpha-1 HC 100 mg

  • Experimental
    Alpha-1 HC 200 mg

    200 mg of aerosolized Alpha-1 HC inhaled daily via nebulizer for 3 weeks.

    Biological: Alpha-1 HC 200 mg

  • Placebo comparator
    Placebo

    Placebo inhaled daily via nebulizer for 3 weeks. Placebo (phosphate buffer saline with polysorbate).

    Biological: Placebo

Interventions

  • Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 100 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.

    Also known as: Alpha1-proteinase inhibitor, alpha1-antitrypsin

  • BiologicalPlacebo

    Phosphate Buffer Saline with Polysorbate (placebo) composed of the same elements listed for Alpha-1 HC, minus the 50 mg/mL of Alpha-1 HC. Placebo inhaled once daily for 21 days for a total of 21 inhaled treatments.

  • Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 200 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.

    Also known as: Alpha1-proteinase inhibitor, alpha1-antitrypsin

06

What researchers measure

Primary outcomes

  1. Adverse Events

    adverse event frequency

    Time frame: 3 weeks

Other outcomes

  1. Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 3

    FEV1 conducted before and after inhalation of the investigational product at study visits.

    Time frame: 3 weeks

  2. Percent Change From Baseline in Forced Vital Capacity (FVC) at Week 3

    FVC conducted before and after inhalation of the investigational product

    Time frame: 3 weeks

07

Results

Posted Feb 8, 2016

Participant flow

A total of 41 subjects provided informed consent and were screened for the study. Eleven (11) subjects were screen failures, and a total of 30 subjects were randomized to one of three treatment groups: 200 mg or 100 mg of Alpha-1 HC or placebo daily.

Participant flow — Overall Study
MilestoneAlpha-1 HC 100 mgAlpha-1 HC 200 mgPlacebo
Started101010
Completed101010
Not completed000

Outcome measures

PrimaryAdverse Events

adverse event frequency

Time frame:
3 weeks
Reported as:
Number · percentage of participants
Adverse Events
percentage of participantsAlpha-1 HC 100 mgAlpha-1 HC 200 mgPlacebo
Adverse Events1008060
Other pre-specifiedPercent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 3

FEV1 conducted before and after inhalation of the investigational product at study visits.

Time frame:
3 weeks
Reported as:
Mean · percent
Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 3
percentAlpha-1 HC 100 mgAlpha-1 HC 200 mgPlacebo
Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 31.5 ± 5.20-2.1 ± 12.280.5 ± 5.91
Other pre-specifiedPercent Change From Baseline in Forced Vital Capacity (FVC) at Week 3

FVC conducted before and after inhalation of the investigational product

Time frame:
3 weeks
Reported as:
Mean · percent
Percent Change From Baseline in Forced Vital Capacity (FVC) at Week 3
percentAlpha-1 HC 100 mgAlpha-1 HC 200 mgPlacebo
Percent Change From Baseline in Forced Vital Capacity (FVC) at Week 31.2 ± 5.23-2.3 ± 11.57-0.9 ± 3.73

Adverse events

Collected over 3 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alpha-1 HC 100 mg—1/10 (10%)10/10 (100%)
Alpha-1 HC 200 mg—1/10 (10%)8/10 (80%)
Placebo—1/10 (10%)6/10 (60%)
Most frequent serious events
Most frequent serious events
EventAlpha-1 HC 100 mgAlpha-1 HC 200 mgPlacebo
ABDOMINAL PAINGastrointestinal disorders0/101/100/10
PULMONARY EXACERBATION/Respiratory, thoracic and mediastinal disorders1/100/101/10
Most frequent other events
Showing 10 of 51
Most frequent other events
EventAlpha-1 HC 100 mgAlpha-1 HC 200 mgPlacebo
HAEMOPTYSISRespiratory, thoracic and mediastinal disorders4/101/101/10
COUGHRespiratory, thoracic and mediastinal disorders3/101/101/10
PULMONARY EXACERBATIONRespiratory, thoracic and mediastinal disorders1/103/100/10
WHEEZINGRespiratory, thoracic and mediastinal disorders3/101/100/10
CHEST DISCOMFORTGeneral disorders0/102/101/10
C-REACTIVE PROTEIN INCREASEDInvestigations0/102/100/10
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders0/100/102/10
PYREXIAGeneral disorders0/100/102/10
MOUTH ULCERATIONGastrointestinal disorders1/100/100/10
VOMITINGGastrointestinal disorders0/101/100/10

Baseline characteristics

Intent-To-Treat (ITT) Population: included all subjects who were randomized (included those withdrawn from treatment for any reason).

Age, Continuous
Age, Continuous(years)Alpha-1 HC 100 mgAlpha-1 HC 200 mgPlaceboTotal
Mean28.2 ± 10.6228.1 ± 11.4329.3 ± 9.9628.5 ± 10.32
Sex: Female, Male
Sex: Female, Male(Participants)Alpha-1 HC 100 mgAlpha-1 HC 200 mgPlaceboTotal
Female86620
Male24410
Region of Enrollment
Region of Enrollment(participants)Alpha-1 HC 100 mgAlpha-1 HC 200 mgPlaceboTotal
United States10101030
08

Study locations

6 sites
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • National Jewish Hospital
    Denver, Colorado 80206, United States
  • Children's Hospital Boston
    Boston, Massachusetts 02115, United States
  • UNC at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Rainbow Babies and Children's Hospital
    Cleveland, Ohio 44106, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2012
First posted
Sep 13, 2012
Start
Aug 2012
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results first posted
Feb 8, 2016
Last update
Feb 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01684410
Responsible party
Sponsor
First posted
Sep 13, 2012
Start date
Aug 2012
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Feb 8, 2016
Last update
Feb 8, 2016

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha 1-Antitrypsin

Start the discussion